🟢 Spero Therapeutics is trading 7.6% up in pre-market — with no clear catalyst identified

Spero Therapeutics is trading at $1.28, up 7.56%, in pre-market, with no clear company-specific catalyst identified.

• The latest company release, dated October 2, covered inducement grants to new employees; it does not clearly explain the rise.
• An October 7, 2026 report recapped the grants and a September analyst price-target increase, identifying neither as a new overnight catalyst.
• Broader markets were mixed, and the available evidence does not establish a market-wide reason for the move.